Posts Tagged ‘buzz stocks’

« Older Entries
Newer Entries »

Penn Millers Holding Corporation (PMIC) to be bought, shares take off

Thursday, September 8th, 2011

Penn Millers Holding Corporation (Nasdaq: PMIC) shares vaulted 23.4% as Thursday’s session wound to a close to $20.12, on word of a possible takeover by ACE Ltd. Volume for the stock totaled 581,000 shares, or about 100 times its daily average.

A news release out Sept. 8 revealed that the company, which provides property and casualty insurance through its wholly owned subsidiary, Penn Millers Insurance Company, today announced that it has entered into a definitive agreement on Sept. 7, to be acquired by a subsidiary of ACE Limited for $20.50 per share in cash.

The purchase price represents a premium of 39% over the $14.75 per share closing price of PMIC on August 15, the date of its announcement that it was reviewing strategic alternatives. It also represents approximately 101% of book value (108% of fully diluted book value) of Penn Millers at June 30.

The release quotes Penn Millers CEO Douglas A. Gaudet thus: “This transaction delivers outstanding returns to our shareholders and additional benefits to our policyholders, agents, brokers, and employees. We are excited to join ACE, one of the largest and most respected insurance companies in the world.

Gaudet continued, “We believe ACE’s national platform and product capabilities will provide strong growth opportunities to our well-established agency network. Our state-of-the-art loss control and claim services in agribusiness and other specialty niches will round out ACE’s agricultural insurance capabilities.”

Based in Wilkes-Barre, Pa. Penn Millers Holding Corporation provides property and casualty insurance through its wholly owned subsidiary, Penn Millers Insurance Company.

Tags: , , , ,
Posted in Financial Stocks | No Comments »

Buyout target Caliper Life Sciences Inc. (CALP) leaps

Thursday, September 8th, 2011

Caliper Life Sciences Inc. (Nasdaq: CALP) surged 40.2% to $10.36 a share after PerkinElmer Inc. (NYSE: PKI) said it would buy the maker of genomic-detection technologies for about $600 million, or $10.50 a share, in cash. Volume for the stock topped 26 million shares, where it normally would trade in 403,000 in an average day.

A news release dated September 8 stated that the Hopkinton, MA-based Caliper was being bought by PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment.

The combined technology platforms will expand PerkinElmer’s deep portfolio of solutions and services for global customers including:

  • Broader offerings for molecular, cellular, animal and tissue imaging to enable translational medicine research;
  • Addition of a world-leading microfluidics platform for genomics and proteomics applications, for improved detection and screening through low sample use and efficiency;
  • High-value sample preparation technologies for key scientific workflow areas such as Next Generation DNA Sequencing

Caliper CEO Kevin Hrusovsky, noted in the same release, “We are delighted to become part of PerkinElmer. For 10 years, Caliper has partnered with strategic customers to develop a compelling suite of discovery technologies for broad life science applications.”

Hrusovsky added, “I am excited by both PerkinElmer’s ability to leverage its global reach for the delivery of solutions and the opportunity to accelerate the development of important advances that make a difference in improving human and environmental health. I am confident this is the correct strategic direction at this time for Caliper customers, shareholders and employees, and we are looking forward to becoming part of one of the leading companies in our industry.”

Hrusovsky is anticipated to join the PerkinElmer senior leadership team following the close of the transaction.

The total purchase price represents a premium of 42% for Caliper Life Sciences shareholders, relative to the closing price of $7.39 on Wednesday, September 7, 2011, the last trading day prior to today’s announcement.
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently.

Tags: , , , , , ,
Posted in Technology Stocks | No Comments »

Conn’s Inc. (CONN) jumps on earnings estimates

Wednesday, September 7th, 2011

Conn’s Inc. (Nasdaq: CONN) shares leapt 33.6% to $7.27 after the electronics and furniture seller projected 2012 earnings above estimates. Volume for the stock topped 926,000 shares, more than triple its daily average.

A news release dated September 7 revealed that the company’s total revenues were $184.4 million, down 13.5% from the same period in the prior fiscal year, on a same store sales decline of 12.8%; However, retail segment retail gross margin increased 320 basis points to 28.9%.

What’s more, adjusted diluted earnings per share were $0.17 for the second quarter of fiscal 2012, excluding the impact of the term loan payoff and store closings, as compared to adjusted diluted earnings per share of $0.06 for the same period in the prior fiscal year, on a higher number of shares outstanding in the current year period.

The Company initiated earnings guidance, for the fiscal year ending January 31, 2012, of adjusted diluted earnings per share of $0.65 to $0.75.

The release quoted Conn’s chairman Theodore Wright as saying, “We are pleased with our progress on improving margins and reducing our cost of capital. While softer industry conditions resulted in sales slightly below our expectations, the changes made to date position us to drive improved profitability.”

The Company is a specialty retailer currently operating 71 retail locations in Texas, Louisiana and Oklahoma: with 23 stores in the Houston area, 18 in the Dallas/Fort Worth Metroplex, eight in San Antonio, three in Austin, five in Southeast Texas, one in Corpus Christi, four in South Texas, six in Louisiana and three in Oklahoma.

Tags: , , ,
Posted in Consumer Discretionary Stocks | No Comments »

Temple Inland Inc. (TIN) jumps on International buyout

Tuesday, September 6th, 2011

Temple Inland Inc. (NYSE: TIN) shares rallied 25.5% to $30.91 a piece Tuesday after International Paper Co. (NYSE: IP) raised its raised its offer for the shipping-box maker. Volume for Temple topped 27.6 million shares, nearly eight times its daily average.

A news release out September 6 noted that the Memphis-based Temple and International announced that they have entered into a definitive merger agreement under which International Paper will acquire all of the outstanding common stock of Temple-Inland for $32.00 per share in cash, plus the assumption of $600 million in Temple-Inland’s year-end debt. The total transaction value is approximately $4.3 billion.

The combination, which has been approved by the Boards of both companies, offers numerous benefits for the shareholders and customers of both companies, and is consistent with International Paper’s focus on achieving and sustaining cost of capital returns throughout the cycle. The transaction is expected to be accretive to International Paper’s shareholders in year one after closing. It is expected to close in the first quarter of 2012.

Temple-Inland Chairman and Chief Executive Officer Doyle R. Simons was quoted in the release as saying, “this transaction creates value for both Temple-Inland and International Paper shareholders. The combined company will be positioned to be a leader in providing high quality products for its customers.”

Temple-Inland Inc. is a manufacturing company focused on corrugated packaging and building products. The fully integrated corrugated packaging operation consists of seven mills and 59 converting facilities.

Tags: , , , , , , , ,
Posted in Consumer Discretionary Stocks, Consumer Staples Stocks | No Comments »

Pharmasset Inc. (VRUS) jumps on drug findings

Tuesday, September 6th, 2011

Pharmasset Inc. (Nasdaq: VRUS) shares rose 5.2% to $67.55 after the drug developer released preliminary findings from a study of its Hepatitis C treatment. Volume for the stock was 658,000 shares, or about half its daily average.

A news release out September 6 noted that the Princeton, New Jersey-based company announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously.

In all, 95 treatment-naive patients with HCV genotype 1 were enrolled into two open-label arms of the PROTON trial, receiving either PSI-7977 200 mg QD (N=48) or 400 mg QD (N=47) for 12 weeks. Individuals in both arms received Peg-IFN/RBV for 24 weeks and were followed post-treatment to assess SVR12.

What’s more, 26 subjects were enrolled in a placebo control arm and are receiving 48 weeks of Peg-IFN/RBV. Results from this study through the SVR12 endpoint are scheduled to be presented as part of a Presidential Plenary Session at the American Association for the Study of Liver Diseases (AASLD) meeting on Tuesday, November 8, 2011.

“I am very pleased with the results of this study which clearly demonstrate the benefit of the 400 mg dose of PSI-7977 with only 24 weeks of interferon for all subjects,” Dr. Eric Lawitz, the study’s principal investigator, was quoted in the release as saying. “HCV therapy is becoming overly complex, and the elimination of 24 weeks of interferon and ribavirin as well as all response guided criteria for patients with HCV genotype 1 would be a welcomed simplification.”

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections.

Tags: , , , , , ,
Posted in Health Care Stocks | No Comments »

« Older Entries
Newer Entries »